EB-1010: Phase II data

Data from the modified intent-to-treat (mITT) population (n=56) of a double-blind, U.S. and European Phase II trial showed that EB-1010 met the primary endpoint of significantly improving MADRS total score at week 6 vs. placebo (18.16 vs. 21.99 points, p=0.028). EB-1010 also met the secondary endpoints of significantly improving CGI-I and anhedonia factor scores vs. placebo (p=0.03 and p=0.049, respectively). EB-1010 was well tolerated with no weight gain or sexual dysfunction associated with treatment. Patients received a titrated dose of once-daily 50 mg EB-1010 for 2 weeks, followed by once-daily 100 mg EB-1010 for 4 weeks, or placebo. Data were presented at the American College of Neuropsychopharmacology meeting in Miami. ...